Savant Capital LLC Has $2.07 Million Stock Holdings in DexCom, Inc. $DXCM

Savant Capital LLC trimmed its holdings in DexCom, Inc. (NASDAQ:DXCM) by 78.7% during the second quarter, Holdings Channel reports. The institutional investor owned 23,725 shares of the medical device company’s stock after selling 87,677 shares during the quarter. Savant Capital LLC’s holdings in DexCom were worth $2,071,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in DXCM. Vanguard Group Inc. raised its holdings in shares of DexCom by 2.0% in the 1st quarter. Vanguard Group Inc. now owns 47,455,899 shares of the medical device company’s stock worth $3,240,763,000 after acquiring an additional 925,882 shares during the last quarter. Jennison Associates LLC boosted its stake in DexCom by 9.4% during the 2nd quarter. Jennison Associates LLC now owns 11,517,546 shares of the medical device company’s stock valued at $1,005,367,000 after purchasing an additional 994,300 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in DexCom by 22.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 10,123,525 shares of the medical device company’s stock worth $691,336,000 after purchasing an additional 1,868,241 shares in the last quarter. Nuveen LLC purchased a new stake in shares of DexCom in the first quarter worth approximately $554,893,000. Finally, Raymond James Financial Inc. raised its stake in shares of DexCom by 21.8% in the first quarter. Raymond James Financial Inc. now owns 3,355,057 shares of the medical device company’s stock worth $229,117,000 after purchasing an additional 601,088 shares during the last quarter. 97.75% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research analysts recently issued reports on the company. JPMorgan Chase & Co. cut their target price on DexCom from $90.00 to $75.00 and set a “neutral” rating on the stock in a research report on Friday, October 31st. Barclays set a $80.00 price objective on shares of DexCom and gave the stock an “equal weight” rating in a report on Monday, November 3rd. Sanford C. Bernstein reiterated an “outperform” rating and issued a $84.00 target price on shares of DexCom in a report on Monday, November 3rd. Wall Street Zen upgraded shares of DexCom from a “buy” rating to a “strong-buy” rating in a report on Saturday. Finally, Wells Fargo & Company set a $93.00 price objective on shares of DexCom and gave the stock an “overweight” rating in a research report on Friday, October 31st. Three research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have given a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $87.62.

DexCom Stock Performance

Shares of DXCM stock opened at $58.13 on Wednesday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.35 and a current ratio of 1.52. The firm has a market cap of $22.67 billion, a price-to-earnings ratio of 40.37, a P/E/G ratio of 1.43 and a beta of 1.40. DexCom, Inc. has a 52 week low of $54.11 and a 52 week high of $93.25. The firm’s 50-day simple moving average is $68.51 and its two-hundred day simple moving average is $77.51.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Thursday, October 30th. The medical device company reported $0.61 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.57 by $0.04. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The company had revenue of $1.21 billion during the quarter, compared to analyst estimates of $1.18 billion. During the same quarter last year, the business posted $0.45 EPS. DexCom’s quarterly revenue was up 21.6% compared to the same quarter last year. DexCom has set its FY 2025 guidance at EPS. As a group, equities analysts forecast that DexCom, Inc. will post 2.03 earnings per share for the current year.

Insider Activity

In other news, COO Jacob Steven Leach purchased 18,200 shares of the business’s stock in a transaction dated Monday, November 10th. The stock was bought at an average price of $55.04 per share, for a total transaction of $1,001,728.00. Following the purchase, the chief operating officer owned 331,697 shares of the company’s stock, valued at $18,256,602.88. The trade was a 5.81% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Kyle Malady sold 667 shares of DexCom stock in a transaction dated Friday, September 5th. The stock was sold at an average price of $80.86, for a total value of $53,933.62. Following the completion of the sale, the director directly owned 22,667 shares of the company’s stock, valued at approximately $1,832,853.62. This trade represents a 2.86% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 9,331 shares of company stock worth $652,085. 0.32% of the stock is owned by company insiders.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.